Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMCL vaccine in high-risk resected melanoma
ACTRN12605000702617Phase 3Active, not recruiting
- Sponsor
- NHMRC Clinical Trials Centre
- Start
- Dec 1987
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of vaccinia melanoma cell lysate vaccine in melanoma (2 arms), sponsored by NHMRC Clinical Trials Centre. Primary endpoints: Disease free interval and Disease free survival. Started Dec 1987; status: active, not recruiting.
02
Drugs
vaccinia melanoma cell lysate vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12605000702617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000702617.